Stocks · News reference
Phathom Pharmaceuticals announced its financial results for the third quarter of 2026, reporting $84.7 million in net revenue and a net loss of $13.9 million.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Filed: 2026-10-29 AccNo: 0001193125-26-436959 Size: 254 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Phathom Pharmaceuticals reported that the FDA has opened a public docket to solicit comments on regulatory issues related to an ANDA for VOQUEZNA, while the company has also intervened in ongoing litigation.